HCW Biologics Inc
Company Profile
Business description
HCW Biologics Inc is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation. It has created novel compounds that represent a new class of drugs that it believes has the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia. The company has developed two proprietary drug discovery and development platforms which it uses to create novel fusion immunotherapeutics: The TOBI (Tissue factOr-Based fusIon) platform, and The T-cell Receptor Beta Chain constant region (TRBC) platform. It operates and manages its business as one reportable segment.
Contact
2929 N. Commerce Parkway
MiramarFL33025
USAT: +1 954 842-2024
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
35
Stocks News & Analysis
stocks
ASX energy giant undervalued despite commissioning challenges
stocks
Undervalued ASX share upgrades guidance
stocks
ASX major bank drives strong quarterly profit
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,112.00 | 79.70 | 0.88% |
| CAC 40 | 8,458.78 | 52.72 | 0.63% |
| DAX 40 | 25,464.01 | 102.98 | 0.41% |
| Dow JONES (US) | 52,878.47 | 668.39 | 1.28% |
| FTSE 100 | 10,871.02 | 89.27 | 0.83% |
| HKSE | 25,310.85 | 103.67 | 0.41% |
| NASDAQ | 24,970.37 | 38.29 | 0.15% |
| Nikkei 225 | 62,364.92 | 2,566.27 | -3.95% |
| NZX 50 Index | 13,861.93 | 11.24 | 0.08% |
| S&P 500 | 7,449.44 | 36.26 | 0.49% |
| S&P/ASX 200 | 8,947.80 | 85.60 | 0.97% |
| SSE Composite Index | 3,813.31 | 44.93 | -1.16% |